We considered comparing the number of initial courses of a drug to other substances to assess whether drugs with greater a priori safety, such as ustekinumab or vedolizumab, were prescribed more often compared to drugs which were considered to have a slightly higher risk of infection, such as TNF-alpha inhibitors. This evidence concerns the gene TNF and infection.